Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 257

1.

Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.

Brunette LL, Mhawech-Fauceglia PY, Ji L, Skeate JG, Brand HE, Lawrenson K, Walia S, Chiriva-Internati M, Groshen S, Roman LD, Kast WM, Da Silva DM.

BMC Cancer. 2018 Oct 11;18(1):970. doi: 10.1186/s12885-018-4880-x.

2.

Cervico-vaginal self-collection in HIV-infected and uninfected women from Tapajós region, Amazon, Brazil: High acceptability, hrHPV diversity and risk factors.

Rodrigues LLS, Morgado MG, Sahasrabuddhe VV, De Paula VS, Oliveira NS, Chavez-Juan E, Da Silva DM, Kast WM, Nicol AF, Pilotto JH.

Gynecol Oncol. 2018 Oct;151(1):102-110. doi: 10.1016/j.ygyno.2018.08.004. Epub 2018 Aug 4.

PMID:
30087059
3.

Heterotetrameric annexin A2/S100A10 (A2t) is essential for oncogenic human papillomavirus trafficking and capsid disassembly, and protects virions from lysosomal degradation.

Taylor JR, Fernandez DJ, Thornton SM, Skeate JG, Lühen KP, Da Silva DM, Langen R, Kast WM.

Sci Rep. 2018 Aug 3;8(1):11642. doi: 10.1038/s41598-018-30051-2.

4.

Nanobody-Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses.

Woodham AW, Cheloha RW, Ling J, Rashidian M, Kolifrath SC, Mesyngier M, Duarte JN, Bader JM, Skeate JG, Da Silva DM, Kast WM, Ploegh HL.

Cancer Immunol Res. 2018 Jul;6(7):870-880. doi: 10.1158/2326-6066.CIR-17-0661. Epub 2018 May 23.

PMID:
29792298
5.

Nano-Pulse Stimulation induces immunogenic cell death in human papillomavirus-transformed tumors and initiates an adaptive immune response.

Skeate JG, Da Silva DM, Chavez-Juan E, Anand S, Nuccitelli R, Kast WM.

PLoS One. 2018 Jan 11;13(1):e0191311. doi: 10.1371/journal.pone.0191311. eCollection 2018.

6.

Syndemic synergy of HPV and other sexually transmitted pathogens in the development of high-grade anal squamous intraepithelial lesions.

McCloskey JC, Kast WM, Flexman JP, McCallum D, French MA, Phillips M.

Papillomavirus Res. 2017 Dec;4:90-98. doi: 10.1016/j.pvr.2017.10.004. Epub 2017 Nov 7.

7.

Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.

Mirandola L, Pedretti E, Figueroa JA, Chiaramonte R, Colombo M, Chapman C, Grizzi F, Patrinicola F, Kast WM, Nguyen DD, Rahman RL, Daver N, Ruvolo P, Post SM, Bresalier RS, Chiriva-Internati M.

Oncotarget. 2017 Aug 10;8(43):74378-74390. doi: 10.18632/oncotarget.20102. eCollection 2017 Sep 26.

8.

A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression.

García-Hernández ML, Uribe-Uribe NO, Espinosa-González R, Kast WM, Khader SA, Rangel-Moreno J.

Front Immunol. 2017 May 17;8:563. doi: 10.3389/fimmu.2017.00563. eCollection 2017.

9.

Annexin A2 antibodies but not inhibitors of the annexin A2 heterotetramer impair productive HIV-1 infection of macrophages in vitro.

Woodham AW, Sanna AM, Taylor JR, Skeate JG, Da Silva DM, Dekker LV, Kast WM.

Virol J. 2016 Nov 18;13(1):187.

10.

Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4.

Pulido MA, DerHartunian MK, Qin Z, Chung EM, Kang DS, Woodham AW, Tsou JA, Klooster R, Akbari O, Wang L, Kast WM, Liu SV, Verschuuren JJGM, Aswad DW, Laird-Offringa IA.

J Neuroimmunol. 2016 Oct 15;299:70-78. doi: 10.1016/j.jneuroim.2016.09.002. Epub 2016 Sep 3.

11.

The Cytoskeletal Adaptor Obscurin-Like 1 Interacts with the Human Papillomavirus 16 (HPV16) Capsid Protein L2 and Is Required for HPV16 Endocytosis.

Wüstenhagen E, Hampe L, Boukhallouk F, Schneider MA, Spoden GA, Negwer I, Koynov K, Kast WM, Florin L.

J Virol. 2016 Nov 14;90(23):10629-10641. doi: 10.1128/JVI.01222-16. Print 2016 Dec 1.

12.

Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment.

Woodham AW, Skeate JG, Sanna AM, Taylor JR, Da Silva DM, Cannon PM, Kast WM.

AIDS Patient Care STDS. 2016 Jul;30(7):291-306. doi: 10.1089/apc.2016.0100. Review.

13.

T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in the absence of costimulation.

Woodham AW, Yan L, Skeate JG, van der Veen D, Brand HH, Wong MK, Da Silva DM, Kast WM.

Papillomavirus Res. 2016 Dec;2:21-30.

14.

Secretory Leukocyte Protease Inhibitor Expression and High-Risk HPV Infection in Anal Lesions of HIV-Positive Patients.

Nicol AF, Brunette LL, Nuovo GJ, Grinsztejn B, Friedman RK, Veloso VG, Cunha CB, Coutinho JR, Vianna-Andrade C, Oliveira NS, Woodham AW, DA Silva DM, Kast WM.

J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):27-33. doi: 10.1097/QAI.0000000000001049. Erratum in: J Acquir Immune Defic Syndr. 2016 Dec 1;73(4):e66.

15.

Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.

Skeate JG, Woodham AW, Einstein MH, Da Silva DM, Kast WM.

Hum Vaccin Immunother. 2016 Jun 2;12(6):1418-29. doi: 10.1080/21645515.2015.1136039. Epub 2016 Feb 2. Review.

16.

Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C.

Da Silva DM, Woodham AW, Rijkee LK, Skeate JG, Taylor JR, Koopman ME, Brand HE, Wong MK, McKee GM, Salazar AM, Kast WM.

Papillomavirus Res. 2015 Dec 1;1:12-21. doi: 10.1016/j.pvr.2015.05.001.

17.

Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells.

Da Silva DM, Woodham AW, Naylor PH, Egan JE, Berinstein NL, Kast WM.

J Interferon Cytokine Res. 2016 May;36(5):291-301. doi: 10.1089/jir.2015.0115. Epub 2015 Dec 10.

18.

Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection.

Skeate JG, Porras TB, Woodham AW, Jang JK, Taylor JR, Brand HE, Kelly TJ, Jung JU, Da Silva DM, Yuan W, Kast WM.

J Gen Virol. 2016 Feb;97(2):422-34. doi: 10.1099/jgv.0.000341. Epub 2015 Nov 10.

19.

Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C.

Da Silva DM, Woodham AW, Skeate JG, Rijkee LK, Taylor JR, Brand HE, Muderspach LI, Roman LD, Yessaian AA, Pham HQ, Matsuo K, Lin YG, McKee GM, Salazar AM, Kast WM.

Clin Immunol. 2015 Dec;161(2):197-208. doi: 10.1016/j.clim.2015.09.003. Epub 2015 Sep 8.

20.

A novel murine model for evaluating bovine papillomavirus prophylactics/therapeutics for equine sarcoid-like tumours.

Bogaert L, Woodham AW, Da Silva DM, Martens A, Meyer E, Kast WM.

J Gen Virol. 2015 Sep;96(9):2764-8. doi: 10.1099/vir.0.000212. Epub 2015 Jun 4.

21.

Small molecule inhibitors of the annexin A2 heterotetramer prevent human papillomavirus type 16 infection.

Woodham AW, Taylor JR, Jimenez AI, Skeate JG, Schmidt T, Brand HE, Da Silva DM, Kast WM.

J Antimicrob Chemother. 2015;70(6):1686-90. doi: 10.1093/jac/dkv045. Epub 2015 Feb 23.

22.

Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes.

Yan L, Da Silva DM, Verma B, Gray A, Brand HE, Skeate JG, Porras TB, Kanodia S, Kast WM.

Prostate. 2015 Feb 15;75(3):280-91. doi: 10.1002/pros.22914. Epub 2014 Nov 14.

23.

Functional analysis of HPV-like particle-activated Langerhans cells in vitro.

Yan L, Woodham AW, Da Silva DM, Kast WM.

Methods Mol Biol. 2015;1249:333-50. doi: 10.1007/978-1-4939-2013-6_25.

24.

Molecular analysis of human papillomavirus virus-like particle activated Langerhans cells in vitro.

Woodham AW, Raff AB, Da Silva DM, Kast WM.

Methods Mol Biol. 2015;1249:135-49. doi: 10.1007/978-1-4939-2013-6_10.

25.

Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression.

Woodham AW, Raff AB, Raff LM, Da Silva DM, Yan L, Skeate JG, Wong MK, Lin YG, Kast WM.

J Immunol. 2014 May 15;192(10):4748-57. doi: 10.4049/jimmunol.1303190. Epub 2014 Apr 9.

26.

Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype.

Da Silva DM, Movius CA, Raff AB, Brand HE, Skeate JG, Wong MK, Kast WM.

Virology. 2014 Mar;452-453:279-86. doi: 10.1016/j.virol.2014.01.031. Epub 2014 Feb 17.

27.

The evolving field of human papillomavirus receptor research: a review of binding and entry.

Raff AB, Woodham AW, Raff LM, Skeate JG, Yan L, Da Silva DM, Schelhaas M, Kast WM.

J Virol. 2013 Jun;87(11):6062-72. doi: 10.1128/JVI.00330-13. Epub 2013 Mar 27. Review.

28.

Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor.

Hoffmann M, Quabius ES, Tribius S, Hebebrand L, Görögh T, Halec G, Kahn T, Hedderich J, Röcken C, Haag J, Waterboer T, Schmitt M, Giuliano AR, Kast WM.

Oncol Rep. 2013 May;29(5):1962-8. doi: 10.3892/or.2013.2327. Epub 2013 Mar 5.

29.

A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies.

Bot A, Ahn M, Bosch M, Brockstedt D, Butterfield LH, Cornforth A, Harrop R, Kast WM, Koya R, Marincola F, Margolin K, McCoy C, Pawelec G, Rothman J, Ramirez-Montagut T, Schlom J, Srivastava P, Wallis S, Walter S, Wang E, Waslif J.

J Transl Med. 2012 Nov 5;10:218. doi: 10.1186/1479-5876-10-218.

30.

Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability.

Pandey A, Kurup A, Shrivastava A, Radhi S, Nguyen DD, Arentz C, D'Chuna N, Hardwick F, D'Souza MJ, Jenkins M, Grizzi F, Kast WM, Cobos E, Rahman R, Chiriva-Internati M, Chiaramonte R, Platonova N.

Int Rev Immunol. 2012 Oct;31(5):302-20. doi: 10.3109/08830185.2012.723511. Review.

PMID:
23083343
31.

The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection.

Woodham AW, Da Silva DM, Skeate JG, Raff AB, Ambroso MR, Brand HE, Isas JM, Langen R, Kast WM.

PLoS One. 2012;7(8):e43519. doi: 10.1371/journal.pone.0043519. Epub 2012 Aug 22.

32.

Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma.

Schutt C, Bumm K, Mirandola L, Bernardini G, Cunha N, Tijani L, Nguyen D, Cordero J, Jenkins MR, Cobos E, Kast WM, Chiriva-Internati M.

Int Rev Immunol. 2012 Feb;31(1):22-42. doi: 10.3109/08830185.2011.637253. Review.

33.

Perspective for prophylaxis and treatment of cervical cancer: an immunological approach.

Jenkins M, Chiriva-Internati M, Mirandola L, Tonroy C, Tedjarati SS, Davis N, D'Cunha N, Tijani L, Hardwick F, Nguyen D, Kast WM, Cobos E.

Int Rev Immunol. 2012 Feb;31(1):3-21. doi: 10.3109/08830185.2011.637254. Review.

34.

In this issue: targeting Human Papilloma Virus-associated disease, from cervical to head and neck carcinoma…and more.

Chiriva-Internati M, Kast WM, Bot A.

Int Rev Immunol. 2012 Feb;31(1):1-2. doi: 10.3109/08830185.2011.646203.

PMID:
22251004
35.

Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia.

Mirandola L, Chiriva-Internati M, Montagna D, Locatelli F, Zecca M, Ranzani M, Basile A, Locati M, Cobos E, Kast WM, Asselta R, Paraboschi EM, Comi P, Chiaramonte R.

J Pathol. 2012 Apr;226(5):713-22. doi: 10.1002/path.3015. Epub 2011 Dec 9.

PMID:
21984373
36.

Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy.

Chiriva-Internati M, Mirandola L, Yu Y, Jenkins MR, Gornati R, Bernardini G, Gioia M, Chiaramonte R, Cannon MJ, Kast WM, Cobos E.

J Immunother. 2011 Jul-Aug;34(6):490-9. doi: 10.1097/CJI.0b013e31821ca76f.

PMID:
21654522
37.

Notch-ing from T-cell to B-cell lymphoid malignancies.

Mirandola L, Comi P, Cobos E, Kast WM, Chiriva-Internati M, Chiaramonte R.

Cancer Lett. 2011 Sep 1;308(1):1-13. doi: 10.1016/j.canlet.2011.05.009. Review.

PMID:
21652011
38.

Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer.

Mirandola L, J Cannon M, Cobos E, Bernardini G, Jenkins MR, Kast WM, Chiriva-Internati M.

Int Rev Immunol. 2011 Apr-Jun;30(2-3):127-37. doi: 10.3109/08830185.2011.572504. Review.

PMID:
21557639
39.

Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies.

Chiriva-Internati M, Mirandola L, Kast WM, Jenkins MR, Cobos E, Cannon MJ.

Int Rev Immunol. 2011 Apr-Jun;30(2-3):71-86. doi: 10.3109/08830185.2011.561507. Review.

PMID:
21557635
40.

Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer.

Chiriva-Internati M, Yu Y, Mirandola L, D'Cunha N, Hardwicke F, Cannon MJ, Cobos E, Kast WM.

Prostate. 2012 Jan;72(1):12-23. doi: 10.1002/pros.21400. Epub 2011 Apr 25.

PMID:
21520158
41.

The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma.

Cordes C, Häsler R, Werner C, Görögh T, Röcken C, Hebebrand L, Kast WM, Hoffmann M, Schreiber S, Ambrosch P.

Int J Oncol. 2011 Jul;39(1):185-91. doi: 10.3892/ijo.2011.1006. Epub 2011 Apr 14.

42.

Bovine papillomavirus DNA can be detected in keratinocytes of equine sarcoid tumors.

Bogaert L, Martens A, Kast WM, Van Marck E, De Cock H.

Vet Microbiol. 2010 Dec 15;146(3-4):269-75. doi: 10.1016/j.vetmic.2010.05.032. Epub 2010 Jun 1.

PMID:
21095508
43.

Prevention is better than cure: the case for clinical trials of therapeutic cancer vaccines in the prophylactic setting.

Gray A, Yan L, Kast WM.

Mol Interv. 2010 Aug;10(4):197-203. doi: 10.1124/mi.10.4.2. Review. No abstract available.

44.

Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.

Chiriva-Internati M, Yu Y, Mirandola L, Jenkins MR, Chapman C, Cannon M, Cobos E, Kast WM.

PLoS One. 2010 May 12;5(5):e10471. doi: 10.1371/journal.pone.0010471.

45.

Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression.

Kanodia S, Da Silva DM, Karamanukyan T, Bogaert L, Fu YX, Kast WM.

Cancer Res. 2010 May 15;70(10):3955-64. doi: 10.1158/0008-5472.CAN-09-3773. Epub 2010 May 11.

46.

Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages.

Gray A, de la Luz Garcia-Hernandez M, van West M, Kanodia S, Hubby B, Kast WM.

Vaccine. 2009 Dec 30;27 Suppl 6:G52-9. doi: 10.1016/j.vaccine.2009.09.106.

47.

Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.

Clark JI, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva DM, Liu PY, Thompson JA, Flaherty LE, Sondak VK.

Cancer. 2010 Jan 15;116(2):424-31. doi: 10.1002/cncr.24739.

48.

A major role for the minor capsid protein of human papillomavirus type 16 in immune escape.

Fahey LM, Raff AB, Da Silva DM, Kast WM.

J Immunol. 2009 Nov 15;183(10):6151-6. doi: 10.4049/jimmunol.0902145. Epub 2009 Oct 28.

49.

Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors.

Smith KA, Meisenburg BL, Tam VL, Pagarigan RR, Wong R, Joea DK, Lantzy L, Carrillo MA, Gross TM, Malyankar UM, Chiang CS, Da Silva DM, Kündig TM, Kast WM, Qiu Z, Bot A.

Clin Cancer Res. 2009 Oct 1;15(19):6167-76. doi: 10.1158/1078-0432.CCR-09-0645. Epub 2009 Sep 29.

50.

Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C.

Adelstein DJ, Ridge JA, Gillison ML, Chaturvedi AK, D'Souza G, Gravitt PE, Westra W, Psyrri A, Kast WM, Koutsky LA, Giuliano A, Krosnick S, Trotti A, Schuller DE, Forastiere A, Ullmann CD.

Head Neck. 2009 Nov;31(11):1393-422. doi: 10.1002/hed.21269. No abstract available.

PMID:
19787782

Supplemental Content

Support Center